The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Sunitinib: From Rational Design to Clinical Efficacy
Abstract
Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor activity. Tyrosine kinase inhibitors such as SU6668 and SU5416 (semaxanib) demonstrated poor pharmacologic properties and limited efficacy; therefore, sunitinib was rationally designed and chosen for its high bioavailability and its nanomolar-range potency against the antiangiogenic receptor tyrosine kinases (RTKs)—vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Sunitinib inhibits other tyrosine kinases including, KIT, FLT3, colony-stimulating factor 1 (CSF-1), and RET, which are involved in a number of malignancies including small-cell lung cancer, GI stromal tumors (GISTs), breast cancer, acute myelogenous leukemia, multiple endocrine neoplasia types 2A and 2B, and familial medullary thyroid carcinoma. Sunitinib demonstrated robust antitumor activity in preclinical studies resulting not only in tumor growth inhibition, but tumor regression in models of colon cancer, non–small-cell lung cancer, melanoma, renal carcinoma, and squamous cell carcinoma, which were associated with inhibition of VEGFR and PDGFR phosphorylation. Clinical activity was demonstrated in neuroendocrine, colon, and breast cancers in phase II studies, whereas definitive efficacy has been demonstrated in advanced renal cell carcinoma and in imatinib-refractory GISTs, leading to US Food and Drug Administration approval of sunitinib for treatment of these two diseases. Studies investigating sunitinib alone in various tumor types and in combination with chemotherapy are ongoing. The clinical benchmarking of this small-molecule inhibitor of members of the split-kinase domain family of RTKs will lead to additional insights regarding the biology, potential biomarkers, and clinical utility of agents that target multiple signaling pathways in tumor, stromal, and endothelial compartments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Rini, B. I., Sosman, J. A., & Motzer, R. J. (2005) · British Journal of Urology · doi:10.1111/j.1464-410x.2005.05616.x · Cited by 51
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Mendel, D. B., Laird, A., Xin, X., Louie, S. G., Christensen, J. G., Li, G., Schreck, R., Abrams, T. J., Ngai, T. J., Lee, L. B., et al. (2003) · PubMed · Cited by 1,961
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Verweij, J., Casali, P. G., Zalcberg, J., LeCesne, A., Reichardt, P., Blay, J.-Y., Issels, R., van Oosterom, A., Hogendoorn, P. C., Van Glabbeke, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17098-0 · Cited by 1,665
Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,634
Buchdunger, E., Cioffi, C. L., Law, N., Stover, D., Ohno-Jones, S., Druker, B. J., & Lydon, N. B. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38879-2 · Cited by 1,274
Faivre, S., Delbaldo, C., Vera, K., Robert, C., Lozahic, S., Lassau, N., Bello, C., Deprimo, S., Brega, N., Massimini, G., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2194 · Cited by 1,164
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo
O'Farrell, A.-M., Abrams, T. J., Yuen, H. A., Ngai, T. J., Louie, S. G., Yee, K. W. H., Wong, L. M., Hong, W., Lee, L. B., Town, A., et al. (2003) · Blood · doi:10.1182/blood-2002-07-2307 · Cited by 864
Wood, J. M., Bold, G., Buchdunger, E., Cozens, R. M., Ferrari, S. M., Frei, J., Hofmann, F., Mestan, J., Mett, H., O'Reilly, T., et al. (2000) · PubMed · Cited by 845
Wedge, S. R., Ogilvie, D., Dukes, M., Kendrew, J., Chester, R., Jackson, J. A., Boffey, S. J., Valentine, P. J., Curwen, J., Musgrove, H. L., et al. (2002) · PubMed · Cited by 798
Abrams, T. J., Lee, L. B., Murray, L. J., Pryer, N., & Cherrington, J. M. (2003) · PubMed · Cited by 636
Heinrich, M. C., Blanke, C. D., Druker, B. J., & Corless, C. L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1692 · Cited by 634
Management of malignant gastrointestinal stromal tumours
Joensuu, H., Fletcher, C., Dimitrijevic, S., Silberman, S., Roberts, P., & Demetri, G. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00899-9 · Cited by 567
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554
Sun, L., Liang, C., Shirazian, S., Zhou, Y., Miller, T., Cui, J., Fukuda, J. Y., Chu, J.-Y., Nematalla, A., Wang, X., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm0204183 · Cited by 521
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 494
Fiedler, W., Serve, H., Döhner, H., Schwittay, M., Ottmann, O. G., O'Farrell, A.-M., Bello, C. L., Allred, R., Manning, W. C., Cherrington, J. M., et al. (2005) · Blood · doi:10.1182/blood-2004-05-1846 · Cited by 490
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Matrix Metalloproteinase-2 Contributes to Cancer Cell Migration on Collagen
Xu, X., Wang, Y., Chen, Z., Sternlicht, M. D., Hidalgo, M., & Steffensen, B. (2005) · Cancer Research · doi:10.1158/0008-5472.130.65.1 · Cited by 413
Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis
Kwiatkowski, D. J. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.446 · Cited by 387
Escudier, B., Szczylik, C., Eisen, T., Stadler, W. M., Schwartz, B., Shan, M., & Bukowski, R. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba4510 · Cited by 348
Antoch, G., Kanja, J., Bauer, S., Kuehl, H., Renzing-Koehler, K., Schuette, J., Bockisch, A., Debatin, J. F., & Freudenberg, L. S. (2004) · PubMed · Cited by 312
O'Farrell, A.-M., Foran, J. M., Fiedler, W., Serve, H. L., Paquette, R. L., Cooper, M. A., Yuen, H. A., Louie, S. G., Kim, H., Nicholas, S., et al. (2003) · PubMed · Cited by 310
Murray, L. J., Abrams, T. J., Long, K. R., Ngai, T. J., Olson, L. M., Hong, W., Keast, P. K., Brassard, J. A., O'Farrell, A. M., Cherrington, J. M., et al. (2003) · Clinical & Experimental Metastasis · doi:10.1023/b:clin.0000006873.65590.68 · Cited by 305
Van Glabbeke, M., Verweij, J., Casali, P. G., Le Cesne, A., Hohenberger, P., Ray-Coquard, I., Schlemmer, M., van Oosterom, A. T., Goldstein, D., Sciot, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.601 · Cited by 280
Kraybill, W. G., Harris, J., Spiro, I. J., Ettinger, D. S., DeLaney, T. F., Blum, R. H., Lucas, D. R., Harmon, D. C., Letson, G. D., & Eisenberg, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5577 · Cited by 278
Turner, K., Moore, J. W., Jones, A., Taylor, C., Cuthbert-Heavens, D., Cheng, H., Leek, R., Gatter, K. C., Maxwell, P. H., Ratcliffe, P. J., et al. (2002) · PubMed · Cited by 269
Regulation and targets of receptor tyrosine kinases
Pawson, T. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)80597-4 · Cited by 264
Abrams, T. J., Murray, L. J., Pesenti, E. A., et al. (2003) · PubMed · Cited by 251
Podar, K., Tonon, G., Sattler, M., Tai, Y.-T., LeGouill, S., Yasui, H., Ishitsuka, K., Kumar, S., Kumar, R., Pandite, L. N., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609329103 · Cited by 216
Giles, F. J., Stopeck, A. T., Silverman, L. R., Lancet, J. E., Cooper, M. A., Hannah, A. L., Cherrington, J. M., O'Farrell, A.-M., Yuen, H. A., Louie, S. G., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3023 · Cited by 200
Angiogenesis inhibitors in clinical development; where are we now and where are we going?
Eskens, F. A. L. M. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601401 · Cited by 197
Smolich, B. D., Yuen, H. A., West, K. A., Giles, F. J., Albitar, M., & Cherrington, J. M. (2001) · Blood · doi:10.1182/blood.v97.5.1413 · Cited by 180
CSF-1 and Its Receptor in Ovarian, Endometrial and Breast Cancer
Kacinski, B. M. (1995) · Annals of Medicine · doi:10.3109/07853899509031941 · Cited by 162
Osusky, K. L., Hallahan, D. E., Fu, A., Ye, F., Shyr, Y., & Geng, L. (2004) · Angiogenesis · doi:10.1007/s10456-004-3149-y · Cited by 153
Rini, B. I., Rixe, O., Bukowski, R. M., Michaelson, M. D., Wilding, G., Hudes, G. R., Bolte, O., Steinfeldt, H. M., Reich, S. D., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.4509 · Cited by 148
Sundberg, C., Ljungström, M., Lindmark, G. E., Gerdin, B., & Rubin, K. (1993) · PubMed · Cited by 143
Bello, C. L., Sherman, L. J., Zhou, J., Verkh, L., Smeraglia, J., Mount, J., & Klamerus, K. J. (2006) · Anti-Cancer Drugs · doi:10.1097/00001813-200603000-00015 · Cited by 136
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD–positive leukemic cells
Yee, K. W. H., Schittenhelm, M. M., O'Farrell, A. M., Town, A., McGreevey, L. S., Bainbridge, T., Cherrington, J. M., & Heinrich, M. C. (2004) · Blood · doi:10.1182/blood-2003-10-3381 · Cited by 121
Socinski, M. A., Novello, S., Sanchez, J. M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7001 · Cited by 101
Carpenter, J. T., Roche, H. H., Campone, M., Colomer, R., Jagiełło-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J. P., & Baselga, J. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.564 · Cited by 99
Krystal, G. W., Honsawek, S., Kiewlich, D., Liang, C., Vasile, S., Sun, L., McMahon, G., & Lipson, K. E. (2001) · PubMed · Cited by 97
Resistance to imatinib (Glivec): update on clinical mechanisms
Weisberg, E., & Griffin, J. D. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00062-1 · Cited by 91
Kinase Inhibitors in Cancer Therapy: A Look Ahead
Sedlacek, H. H. (2000) · Drugs · doi:10.2165/00003495-200059030-00004 · Cited by 90
Sulzbacher, I., Birner, P., Träxler, M., Marberger, M., & Haitel, A. (2003) · American Journal of Clinical Pathology · doi:10.1309/lq9e-mk8q-ke75-nggx · Cited by 84
Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
Moss, K. G., Toner, G. C., Cherrington, J. M., Mendel, D. B., & Laird, A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.052530 · Cited by 81
Imatinib inhibits various types of activating mutant kit found in gastrointestinal stromal tumors
Chen, H., Isozaki, K., Kinoshita, K., Ohashi, A., Shinomura, Y., Matsuzawa, Y., Kitamura, Y., & Hirota, S. (2003) · International Journal of Cancer · doi:10.1002/ijc.11025 · Cited by 70
Sulzbacher, I., Birner, P., Träxler, M., Marberger, M., & Haitel, A. (2003) · American Journal of Clinical Pathology · doi:10.1309/lq9emk8qke75nggx · Cited by 63
The vascular endothelial growth factor family and its receptors
Parikh, A. A., & Ellis, L. M. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2004.06.004 · Cited by 61
Novel treatments for metastatic renal cell carcinoma
van Spronsen, D. J., Mulders, P., & Mulder, P. H. M. D. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.04.002 · Cited by 51
Morimoto, A. M., Tan, N., West, K. A., McArthur, G. A., Toner, G. C., Manning, W. C., Smolich, B. D., & Cherrington, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207268 · Cited by 46
Shaheen, P. E., Tamaskar, I., Salas, R. N., Rini, B. I., Garcia, J., Wood, L., Dreicer, R., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.4605 · Cited by 26
Wakelee, H. A., & Schiller, J. H. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.s.005 · Cited by 23
SU11248 and AG013736: Current Data and Future Trials in Renal Cell Carcinoma
Rini, B. I. (2005) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2005.n.029 · Cited by 17
The expression of cadherins in human neuroblastoma cell lines and clinical tumors.
Shimono, R., Matsubara, S., Takamatsu, H., Fukushige, T., & Ozawa, M. (2000) · PubMed · Cited by 12
Cited by
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181
The FGF family: biology, pathophysiology and therapy
Beenken, A., & Mohammadi, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2792 · Cited by 1,945
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
Chu, T. F., Rupnick, M. A., Kerkela, R., Dallabrida, S. M., Zurakowski, D., Nguyen, L., Woulfe, K., Pravda, E., Cassiola, F., Desai, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61865-0 · Cited by 1,083
Metadata
- Authors
- Chow, L. Q. M., & Eckhardt, S. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-03-01
- Volume
- 25
- Issue
- 7
- Pages
- 884-896
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153331460
- Cited by
- 883
- References
- 60
- FWCI
- 28.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.